@lua459123: #grace #faith #praise #grace

🇰🇪Lau🤍
🇰🇪Lau🤍
Open In TikTok:
Region: KE
Thursday 05 November 2026 17:14:15 GMT
32953
1713
42
368

Music

Download

Comments

dorothylitswa
dorothylitswa :
Hallelujah
2026-11-06 09:04:26
1
soitoibor
soit oibor :
oh yes Amen
2026-11-06 06:38:05
1
efrainterry1
🍒TERRY❤️🌹 :
God,your daughter is greatful 🙏
2026-11-06 06:46:39
1
joseph.roimen
RM :
absolutely
2026-11-06 07:33:11
1
joyce.njenga40
Joyce Njenga :
Glory unto my saviour
2026-11-06 10:53:58
0
roserutto
ROSE RUTTO :
mungu uinuliwe milele
2026-11-06 07:26:23
2
tylerwholesalers
Tyler wholesalers :
Lord just receive my Thanks Giving
2026-11-06 06:16:45
2
abugribelinda352
[email protected] :
Oh yeah God
2026-11-06 10:01:46
1
monicapetra.aloyo
Monicapetra Aloyo :
Amen and Amen 🙏🏼🙏🏼🙏🏼🙏🏼🙏🏼🙏🏼🙏🏼🙏🏼🙏🏼
2026-11-06 07:01:08
1
dianadee816
Dee💖💖💖 :
Ameen
2026-11-06 05:20:51
2
.tiktoksurveyormuttio
Surveyor Muttio :
ooh true
2026-11-06 06:56:17
1
jaymoe.ke
jaymoe :
Amen
2026-11-06 07:20:26
1
isaacpulei
IZOH..PULEI ✝️ :
sure he is a faithful GOD🙏
2026-11-05 18:09:30
2
blessed.mom83
blessed mom :
true and amen
2026-11-06 11:16:35
0
robin.lihanda
Robin Lihanda :
Amina
2026-11-05 19:56:05
1
yunesnyasili
Yunes Nyasili :
Na ainuliwe milele na milele
2026-11-06 10:45:23
0
ndunge1234
@ndunge 1234 :
AMEN 🙏
2026-11-06 06:01:21
1
sirme830
It's Tirop :
Amen Amen Amen
2026-11-06 11:17:27
0
arapubenard352
arapubenard352 :
👑👑👑👑👑👑🙌
2026-11-06 09:26:23
1
winniemuli1
Winnie :
[Pray]
2026-11-06 07:52:38
1
sarahmutongoi
sarahmutongoi :
🤲🤲
2026-11-06 06:24:19
1
carolinekarimi41
Carolinekarimi :
🥰🥰🥰
2026-11-06 02:16:13
1
risebeyondlimits56
Rising Motivation :
[Gesture OK][Gesture OK][Gesture OK]
2026-11-05 17:58:45
1
elizabethnasirumb
elizabethnasirumb :
🙏🙏🙏🙌🙌
2026-11-06 11:18:07
0
To see more videos from user @lua459123, please go to the Tikwm homepage.

Other Videos

Patients who had lost most of their hair — with no meaningful regrowth for at least six months — got some of it back after taking a pill originally designed for arthritis.   The drug is upadacitinib, sold as Rinvoq, a JAK inhibitor that blocks specific proteins driving the immune overreaction behind both rheumatoid arthritis and alopecia areata — an autoimmune disease where the body's immune system mistakenly attacks its own hair follicles, sometimes stripping the scalp, eyebrows, and body hair entirely.   Researchers ran two Phase 3 trials, UP-AA1 and UP-AA2, spanning 237 clinical centers across 25 to 28 countries in Asia, Europe, and North and South America, enrolling 1,399 participants aged 12 to 64. Every patient had already lost at least half their scalp hair — a severity threshold that excludes the milder cases most existing treatments already handle reasonably well.   At the higher 30-milligram dose, 55% of patients regrew at least 80% of their scalp hair within 24 weeks, and up to 23% achieved complete, 100% regrowth — a genuinely rare outcome in alopecia treatment. The placebo group, by comparison, saw only about 2% reach that same threshold. The results also outperformed every other JAK inhibitor currently approved for the condition: baricitinib achieved 35-39% response rates, deuruxolitinib 31%, and ritlecitinib 23%, making upadacitinib the strongest response rate documented for this specific drug class so far.   The EU has already approved upadacitinib specifically for alopecia areata based on these results. In the U.S., AbbVie submitted its application to the FDA in April 2026, with a decision expected as early as 2027 — until then, U.S. doctors can prescribe it off-label, though insurance coverage varies.   For a disease with no cure and historically limited options for its most severe cases, a drug that already existed for a completely different condition may turn out to be the most effective treatment alopecia areata has seen yet.   source: King, B., et al. (2026). Upadacitinib for Severe Alopecia Areata (UP-AA1 and UP-AA2). JAMA Dermatology.
Patients who had lost most of their hair — with no meaningful regrowth for at least six months — got some of it back after taking a pill originally designed for arthritis.   The drug is upadacitinib, sold as Rinvoq, a JAK inhibitor that blocks specific proteins driving the immune overreaction behind both rheumatoid arthritis and alopecia areata — an autoimmune disease where the body's immune system mistakenly attacks its own hair follicles, sometimes stripping the scalp, eyebrows, and body hair entirely.   Researchers ran two Phase 3 trials, UP-AA1 and UP-AA2, spanning 237 clinical centers across 25 to 28 countries in Asia, Europe, and North and South America, enrolling 1,399 participants aged 12 to 64. Every patient had already lost at least half their scalp hair — a severity threshold that excludes the milder cases most existing treatments already handle reasonably well.   At the higher 30-milligram dose, 55% of patients regrew at least 80% of their scalp hair within 24 weeks, and up to 23% achieved complete, 100% regrowth — a genuinely rare outcome in alopecia treatment. The placebo group, by comparison, saw only about 2% reach that same threshold. The results also outperformed every other JAK inhibitor currently approved for the condition: baricitinib achieved 35-39% response rates, deuruxolitinib 31%, and ritlecitinib 23%, making upadacitinib the strongest response rate documented for this specific drug class so far.   The EU has already approved upadacitinib specifically for alopecia areata based on these results. In the U.S., AbbVie submitted its application to the FDA in April 2026, with a decision expected as early as 2027 — until then, U.S. doctors can prescribe it off-label, though insurance coverage varies.   For a disease with no cure and historically limited options for its most severe cases, a drug that already existed for a completely different condition may turn out to be the most effective treatment alopecia areata has seen yet.   source: King, B., et al. (2026). Upadacitinib for Severe Alopecia Areata (UP-AA1 and UP-AA2). JAMA Dermatology.

About